Is TB-500 Legal in South Carolina?
HealthRX.com
TB-500 has no federal clearance to be compounded
See the public record for TB-500
At a glance
- FDA approval / None; FDA found no approved drug containing TB-500 in the US and no approved product in Canada, Australia, the UK or the listed European countries, or authorized by the European Medicines Agency [1]
- FDA pharmacy bulk-substance list / Not on it, and in none of the three interim-policy categories [2][4]
- FDA outsourcing-facility list / Not on it [3]
- Safety-risk page / In the 'nominated but withdrawn' table, not the active category 2 table [7]
- July 2026 advisory vote / Favored adding it; advisory only and nonbinding [8][5]
- HHS draft policy / Filed October 28, 2026; nonbinding, not an approval [5][6]
- Sport / Prohibited at all times by WADA under S2.3 [9][10]
Where does TB-500 stand under FDA's compounding rules?
A state-licensed pharmacy or physician may compound only with a bulk substance that meets a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on FDA's list of bulk substances that can be used in compounding [4]. FDA's July 2026 review found no monograph and no approved drug containing TB-500 [1], and the peptide sits in none of the three categories of FDA's interim policy, so the policy under which FDA does not intend to act against qualifying compounders does not cover it [2][4]. Outsourcing facilities work from a separate list, and TB-500 is not on that one either [3].
Is it on FDA's safety-risk page?
Yes, in the table of substances previously in category 2 whose nominators withdrew them: 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' [7]. It is not in the active category 2 table, and removal was not a finding that it is safe [7]. FDA's stated concerns were that it had identified no human exposure data, lacked important safety information, and that injectable peptides may pose an immunogenicity risk from aggregation and peptide-related impurities [7].
Did the July 2026 vote or the draft HHS policy make it legal?
Neither did. FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding TB-500 to the list, against FDA staff's recommendation; the vote is advice only, adding a substance takes formal rulemaking, and TB-500 is not on the list [8][5][1]. HHS then filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192, publication scheduled for October 30, with comments due two weeks after publication) that names TB-500 among six peptides and covers the acetate form given subcutaneously or intramuscularly [5][6]. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that meets conditions such as a single active ingredient, a patient-specific prescription, and a certificate of analysis from an FDA-registered manufacturer [5][6]. The notice also says it 'does not establish any rights for any person and is not binding on HHS or the public' [5].
What does South Carolina law say?
This page cites no South Carolina statute, regulation or board guidance that names TB-500 or thymosin beta-4. The federal compounding conditions above are written for state-licensed pharmacies and physicians [4], which is the group a South Carolina-licensed practitioner belongs to.
Questions worth asking
Is it banned in sport?
Yes. WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times in and out of competition, and it stays on the 2027 List [9][10].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Does the draft HHS policy make TB-500 legal to compound?
Is there any human evidence for TB-500?
Do trials of thymosin beta-4 show that TB-500 works?
Is TB-500 approved anywhere else?
References
Show all 11 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.